PhaseV debuted an AI offering called AI Conductor to automate clinical development tasks, aiming to harmonize data across studies and make submissions “submission-ready from the start.” The platform is designed to support protocol development, ICH E9 compliance, and case report generation by integrating with PhaseV’s AI-based clinical trial platform. PhaseV said the technology draws from a knowledge base and enforces document consistency. PhaseV’s launch follows its earlier €50 million fundraising, with investors including Accel and Insight Partners, and it arrives as the market sees accelerating rollout of AI tooling for clinical trial operations and regulatory readiness.